Radiation Therapy, Docetaxel, and Hormone Therapy in High-Risk Locally Advanced Metastasized Prostate Cancer

NCT ID: NCT00482807

Last Updated: 2023-11-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 9 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2004-08-31
• Study Completion Date: 2010-03-09

Brief Summary

RATIONALE: Specialized radiation therapy that delivers a high- dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as goserelin and bicalutamide, may lessen the amount of androgens made by the body. Giving radiation therapy together with chemotherapy and hormone therapy may kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of docetaxel when given together with intensity-modulated radiation therapy and hormone therapy in treating patients with high-risk locally advanced prostate cancer with pelvic lymph node metastasis.

Detailed Description

OBJECTIVES:

Primary

• Determine, preliminarily, the grade III or IV toxicity rate of concurrent extended-field intensity-modulated radiotherapy (IMRT), docetaxel, and androgen deprivation therapy in patients with high-risk, locally advanced prostate cancer with pelvic lymph node metastasis.

Secondary

• Determine, preliminarily, the progression-free survival of patients treated with this regimen.
• Determine the maximum tolerated dose of docetaxel when administered with concurrent IMRT in this patients.

OUTLINE: This is a dose-escalation study of docetaxel.

Patients receive combined androgen deprivation therapy (if not already on combined hormonal therapy) comprising goserelin acetate* subcutaneously once every 3 months for up to 2 years and oral bicalutamide once daily beginning on day 1 and continuing until the completion of radiotherapy. Beginning at approximately week 9 of androgen deprivation therapy, patients receive docetaxel IV over 1 hour once weekly for up to 9 weeks. Concurrently with chemotherapy, patients undergo intensity-modulated radiotherapy 5 days a week for up to 45 fractions (9 weeks).

Cohorts of 3-6 patients receive escalating doses of docetaxel until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

Note: *Not required for patients who have undergone bilateral orchiectomy

After completion of study therapy, patients are followed periodically for 5 years.

Conditions

Prostate Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Docetaxel, intensity-modulated radiation therapy and hormone therapy

This phase I trial is studying the side effects and best dose of docetaxel when given together with intensity-modulated radiation therapy and hormone therapy in treating patients with high-risk locally advanced prostate cancer with pelvic lymph node metastasis.

Group Type: EXPERIMENTAL

bicalutamide

Intervention Type: DRUG

docetaxel

Intervention Type: DRUG

goserelin

Intervention Type: DRUG

intensity-modulated radiation therapy

Intervention Type: RADIATION

Interventions

bicalutamide

Intervention Type: DRUG

docetaxel

Intervention Type: DRUG

goserelin

Intervention Type: DRUG

intensity-modulated radiation therapy

Intervention Type: RADIATION

Other Intervention Names

Casodex; Docefrez, Taxotere; Zoladex

Eligibility Criteria

Inclusion Criteria

• Histologically confirmed adenocarcinoma of the prostate

o Locally advanced disease (T1 -T3b, N1 or N2, M0) at high risk for recurrence

1. Biopsy-proven pelvic lymph node involvement

2. No T4 lesion

• Prior androgen suppression within the past 14 months is allowed provided the following criterion is met:

o No biochemical evidence of PSA progression after androgen withdrawal

1. PSA progression, defined as 2 consecutive rising PSA values > 4.0 ng/mL taken ≥ 2 weeks apart

• Karnofsky performance status 80-100%
• absolute neutrophil count (ANC) ≥ 1,500/mm³
• Hemoglobin ≥ 10 g/dL
• Platelet count > 100,000/mm³
• Bilirubin normal
• Fertile patients must use effective contraception during and for ≥ 3 months after completion of study treatment
• Meets 1 of the following criteria:
• Alkaline phosphatase (AP) normal and aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 5 times upper limit of normal (ULN)
• AP ≤ 2.5 times ULN AND AST or ALT ≤ 1.5 times ULN
• AP ≤ 5 times ULN AND AST or ALT normal

Exclusion Criteria

• No evidence of distant metastasis, including any of the following:

• Bone metastasis
• Pathologic or radiographic evidence of lymph node involvement above the L4 - L5 interspace
• No peripheral neuropathy > grade 1
• No significant comorbidity that would preclude radiotherapy
• No other prior malignancy except nonmelanoma skin cancer or any other cancer for which the patient has been disease-free for the past 5 years
• No hypersensitivity to docetaxel or other drugs formulated with polysorbate 80
• No history of Crohn's disease, ulcerative colitis, or irritable bowel syndrome
• No unrepaired inguinal hernia
• No prior pelvic or abdominal radiotherapy or prostate brachytherapy implant
• No prior prostatectomy
• No prior pelvic or abdominal surgery that resulted in excessive amounts of small intestine located within the pelvis
• No other concurrent investigational agents

• Minimum Eligible Age: 19 Years
• Maximum Eligible Age: 120 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: collaborator

University of Nebraska

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ralph Hauke, MD

Role: PRINCIPAL_INVESTIGATOR

University of Nebraska

Elizabeth C Reed, MD

Role: STUDY_CHAIR

University of Nebraska

Locations

University of Nebraska Medical Center

Omaha, Nebraska, United States

Countries

United States

Other Identifiers

P30CA036727

Identifier Type: NIH

Identifier Source: secondary_id

View Link

0195-04-FB

Identifier Type: -

Identifier Source: org_study_id